Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

  • Carlos A. Jiménez-Ruiz | victorina@ctv.es Tobacco Researching Group of the Spanish Respiratory Society, Smoking Cessation Service, Spain.
  • Marcos Garcia Rueda Hospital Carlos Haya, Smoking Unit, Pulmonology Department., Spain.
  • Manuel A. Martinez Muñiz Hospital San Agustín-Avilés, Smoking Unit, Pulmonology Department, Spain.
  • Jacobo Sellarés Hospital Clinic Barcelona, Pulmonology Department, Spain.
  • Maria A. Jiménez-Fuentes Hospital Universitario Valle de Hebron, Spain.
  • Lourdes Lázaro Asegurado Hospital Universitario Burgos, Pulmonology Department, Spain.
  • Esther Rodríguez Gonzalez Hospital Vall d'Hebrón, Pulmonology Department, Spain.
  • Concepción Rodriguez Garcia Hospital San Agustín-Avilés, Smoking Unit, Pulmonology Department, Spain.
  • Oriol Armengol ABS Poblenou, Spain.
  • Emilia Abad Hospital Clinic Barcelona, Pulmonology Department, Spain.
  • Teresa Peña Hospital Universitario Burgos, Pulmonology Department, Spain.
  • Adolfo Domenech del Rio Hospital Carlos Haya, Smoking Unit, Pulmonology Department, Spain.
  • Juan A. Riesco Miranda Hospital San Pedro de Alcantara, Smoking Unit, Pulmonology Department, Spain.

Abstract

A large number of COPD patients are smokers. The particular characteristics of this group as well as their need to quit usually require psychological counselling and pharmacological treatment to achieve abstinence and, often, intensively. Little information is available about this issue.  The main objective of the study was to evaluate the effectiveness of varenicline after 24 weeks of treatment, with continuous abstinence between weeks 9 and 24.  This study was a post-authorization, open label, observational study of prospective follow-up. Patients included were smokers with severe or very severe COPD criteria who were treated with varenicline for 24 weeks, i.e. with a 12-week extension over the usual treatment.  The outcomes in the population of subjects completing 24 weeks of follow-up were at week 24: continuous abstinence 36.8%, 7 days point prevalence abstinence 65.7%, and continuous smoking 31.5%.The outcomes in the intention-to-treat population included at baseline were: continuous abstinence 17.7% of patients, 7 days point prevalence abstinence 31.6%, continuous smoking 15.1% and not valid/unknown 51.8%.  The mean CAT score at week 24 was 15 and reduction from the baseline was 3.77 (paired T test, p<0.01). The most common adverse events reported were nausea, vivid dreams, stomach ache, insomnia, headache and vomiting.  Patients included in VALUE were active smokers despite all of them had a severe COPD which suggests a very high degree of dependence. Although the study do not allow to infer the results to the global population of smokers with severe COPD, the outcomes have shown that, at 24 weeks follow up 36.8% of the patients were successful in quitting but from 79 patients enrolled initially only 17.7% quit. 

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2017-12-19
Info
Issue
Section
Pneumology - Original Articles
Keywords:
COPD, smoking cessation, Varenicline.
Statistics
  • Abstract views: 816

  • PDF: 495
  • Supplementary: 90
How to Cite
Jiménez-Ruiz, C. A., Garcia Rueda, M., Martinez Muñiz, M. A., Sellarés, J., Jiménez-Fuentes, M. A., Lázaro Asegurado, L., Rodríguez Gonzalez, E., Rodriguez Garcia, C., Armengol, O., Abad, E., Peña, T., Domenech del Rio, A., & Riesco Miranda, J. A. (2017). Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study. Monaldi Archives for Chest Disease, 87(3). https://doi.org/10.4081/monaldi.2017.874